NASDAQ · IOVA
Iovance Biotherapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IOVA: Nov 05, 2026
Iovance Biotherapeutics, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.25.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $-0.05 | $-0.13 | 3 |
| Dec 2026 | $-0.11 | $-0.10 | $-0.12 | 3 |
| Mar 2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Jun 2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat · RTTNews- Zacks · Oct 30, 10:05 AM EDTGILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthGilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
- Zacks · Oct 30, 9:29 AM EDTINSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceInsmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
- Zacks · Oct 29, 4:35 PM EDTIllumina (ILMN) Q3 Earnings Beat EstimatesIllumina (ILMN) delivered earnings and revenue surprises of +5.88% and -0.76%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Oct 29, 1:54 PM EDTThese 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay AwayModerna’s earnings prospects don’t justify its current market cap.
- MarketBeat · Oct 29, 1:01 PM EDTIovance’s Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA FilingWhy 2 Small Biotechs May Hold the Key to New Cancer TreatmentsIovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a suppl
- Zacks · Oct 29, 11:31 AM EDTAmarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
- Zacks · Oct 29, 9:43 AM EDTBHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesBausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
- Zacks · Oct 29, 9:22 AM EDTRecursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
- Zacks · Oct 29, 9:00 AM EDTIovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 28, 11:38 PM EDTIovance To Highlight Positive TIL Therapy Readout Today In Metastatic Lung Cancer; Stock Up(RTTNews) – Iovance Biotherapeutics, Inc. (IOVA) announced that it will host a conference call and live audio webcast on October 29, 2026, at 8:30 a.m. ET to discuss positive results from the Phase 2 registrational cohorts of its tumor- infiltrating lymphocyte (TIL) therapy lifil
- Zacks · Oct 28, 10:50 AM EDTLiquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
- Zacks · Oct 27, 9:00 AM EDTBest Momentum Stocks to Buy for October 27thIOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Iovance Biotherapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.